Glucose-dependent Insulinotropic Polypeptide
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT07411560 | Feb 2026 → Jan 2027 expected | obesity disorder | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 1 | NCT01880827 | Jan 2013 → Nov 2015 | obesity disorder, type 2 diabetes mellitus | Turku University Hospital | Completed | No outcome recorded |
| Phase 1 | NCT01951716 | Jan 2013 → Jul 2018 | — | Washington University School of Medicine | Withdrawn | No outcome recorded |
| Phase 1 | NCT00949663 | Oct 2009 → Feb 2014 | type 2 diabetes mellitus | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT00798915 | Dec 2008 → Dec 2012 | diabetes mellitus | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT02673554 | May 2004 → Dec 2008 | type 2 diabetes mellitus | Diabeteszentrum Bad Lauterberg im Harz | Completed | No outcome recorded |
| Phase 1 | NCT00239707 | Feb 2003 → Dec 2006 | type 2 diabetes mellitus | National Institute on Aging (NIA) | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01048268 | Dec 2009 → Apr 2014 | diabetes mellitus | University Hospital, Gentofte, Copenhagen | Completed | No outcome recorded |
| Phase not applicable3 trials · 1 met primary | ||||||
| — | NCT07398300 | Mar 2026 → Mar 2027 expected | type 2 diabetes mellitus | Rigshospitalet, Denmark | Recruiting | No outcome recorded |
| — | NCT01851694 | May 2013 → Dec 2026 expected | cystic fibrosis, exocrine pancreatic insufficiency | University of Pennsylvania | Recruiting | No outcome recorded |
| — | NCT00612950 | Oct 2006 → Feb 2007 | type 2 diabetes mellitus | Hvidovre University Hospital | Completed | Met primary |
| Comparator or background therapy2 trials | ||||||
| — | NCT06881472 Comparator | Jan 2025 → Jan 2026 | type 1 diabetes mellitus | Asger Lund, MD | Completed | No outcome recorded |
| — | NCT03081676 Comparator | Mar 2017 → Jun 2018 | maturity-onset diabetes of the young type 3 | University Hospital, Gentofte, Copenhagen | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 17 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | glucose-dependent insulinotropic polypeptide | “Intravenous infusion of glucose-dependent insulinotropic polypeptide (GIP) consisting of a priming dose of 18 pmol/kg/min for 10 minutes followed by a steady-state infusion of...” NCT07398300 ↗12“Whether the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) can enhance pancreatic islet function in cystic fibrosis...” PMID 35796669 ↗ Oct 2022 “This study tested the hypothesis that glucose-dependent insulinotropic polypeptide (GIP) is involved in diabetes-associated multiislet hormone dysregulation.” PMID 24712564 ↗ Apr 2014 “Glucose-dependent Insulinotropic Polypeptide (GIP) and xenin-25 are peptide hormones produced/released from your intestines” NCT01951716 ↗ “infusion of exogenous glucose-dependent insulinotropic polypeptide (GIP)” PMID 28096259 ↗ Jan 2017 “glucose-dependent insulinotropic polypeptide (GIP)” NCT02673554 ↗ |
| Known as | GIP | “Glucose-dependent insulinotropic polypeptide (GIP) has been suggested to stimulate the secretion of pancreatic polypeptide (PP)” PMID 31665480 ↗ Mar 20207“Glucose-dependent Insulinotropic Polypeptide (GIP)” NCT07411560 ↗ |
| Known as | GIP1-42 | “To determine whether human GIP1-42 (hGIP) stimulates PP secretion.” PMID 31665480 ↗ Mar 2020 |
| Known as | hGIP | “To determine whether human GIP1-42 (hGIP) stimulates PP secretion.” PMID 31665480 ↗ Mar 2020 |
| Action | Activate | “Long-acting Subcutaneous Glucose-dependent Insulinotropic Polypeptide Receptor Agonist (GIP RA)” NCT07411560 ↗ |
| Modality | Peptide | “Both human GIP and the modified GIP (GIP analog) are manufactured by peptide synthesis techniques (not extracted from human gut and not recombinant technology).” NCT00239707 ↗ |
| Route | Intravenous | “An additional intravenous line will be placed for the infusion of either the normal saline, GIP or GIP analog over a period of 3 hours.” NCT00239707 ↗ |